THE EFFICACY OF NONINVASIVE VOLUME TARGETED VENTILATION IN PATIENTS WITH CHRONIC RESPIRATORY FAILURE DUE TO KYPHOSCOLIOSIS

P.Piesiak, A.Brzecka, M.Kosacka, R.Jankowska

Department of Pulmonology and Lung Cancer, Medical University in Wroclaw, ul. Grabiszynska 105, Wroclaw 53-439, Poland, ppiesiak@tlen.pl

INTRODUCTION. Severe kyphoscoliosis can cause chronic respiratory failure (CRF). Noninvasive mechanical ventilation (NIMV) is a new optional treatment for such patients. The aim of this study was to evaluate the effectiveness of average volume-assured pressure support (AVAPS) NIMV in patients with kyphoscoliotic CRF.

MATERIAL. Material of the study consisted of 12 patients (age 48.9 ± 11.0 , body mass index $27.5\pm7.9 \text{ kg/m}^2$) with advanced kyphoscoliosis complicated by severe CRF (PaO₂ - 6.68 ± 0.34 kPa, SaO₂ - 81.7 ± 3.1 %, PaCO₂ - 9.51 ± 1.08 kPa) treated by AVAPS NIMV. The efficacy of NIMV was evaluated on 5-th day and after 1 year home treatment.

RESULTS. We observed a significant improvement of diurnal PaO₂ and PaCO₂ on 5-th day of NIMV (respectively the increase of 1.39 ± 0.26 kPa and the decrease of 1.81 ± 0.80 kPa, $p \le 0.05$) and after 1 one year of home NIMV (respectively the increase of $2,07\pm0.46$ kPa and the decrease of 2.68 ± 0.85 kPa, $p \le 0.05$). There was a significant increase of mean blood oxygen saturation during sleep on 5-th day ($86.2\pm7.2\%$) and after 1 year of treatment ($89.4\pm1.2\%$) compared to the baseline values ($83.2\pm3.2\%$). The forced vital capacity increased after 1 year of therapy compared with baseline values (1024 ± 258 ml vs 908 ± 267 ml, respectively; p < 0.05). The NIMV tolerance was high and no patient discontinued the treatment during the observation period (1-5 years).

CONCLUSION. AVAPS NIMV is an effective and well tolerated treatment option in kyphoscoliotic patients with chronic respiratory failure resulting in a rapid and long-term improvement of daytime and nocturnal blood gas exchange.